
LifeTech Scientific Corporation (1302.HK)
1302.HK Stock Price Chart
Explore LifeTech Scientific Corporation interactive price chart. Choose custom timeframes to analyze 1302.HK price movements and trends.
1302.HK Company Profile
Discover essential business fundamentals and corporate details for LifeTech Scientific Corporation (1302.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
10 Nov 2011
Employees
1.40K
Website
https://www.lifetechmed.comCEO
Yuehui Xie
Description
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The company operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. Its products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, Heart, and Konara-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; delivery systems, such as Fustar steerable and SteerEase introducers; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; LawMax dilators; and SeQure snare systems, as well as pacemakers. The company is also involved in the biomedical research and development; manufacturing and trading of materials for hemp; staff training and internal personnel management business; information consulting for investors; and manufacturing and trading of medical devices, as well as technical, consulting, and technology services. It has operations in Mainland China, India, rest of Asia, Europe, South America, Africa, and internationally. LifeTech Scientific Corporation was founded in 1999 and is headquartered in Shenzhen, the People's Republic of China.
1302.HK Financial Timeline
Browse a chronological timeline of LifeTech Scientific Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 27 Mar 2025
EPS came in at $0.00 , while revenue for the quarter reached $692.39M .
Earnings released on 30 Aug 2024
EPS came in at $0.05 , while revenue for the quarter reached $701.08M .
Earnings released on 2 Apr 2024
EPS came in at $0.01 , while revenue for the quarter reached $694.71M , beating expectations by +1.21K%.
Earnings released on 30 Aug 2023
EPS came in at $0.05 , while revenue for the quarter reached $691.57M , beating expectations by +1.20K%.
Earnings released on 29 Mar 2023
EPS came in at $0.03 , while revenue for the quarter reached $617.40M , beating expectations by +1.06K%.
Earnings released on 30 Aug 2022
EPS came in at $0.06 , while revenue for the quarter reached $649.97M , beating expectations by +1.13K%.
Earnings released on 30 Mar 2022
EPS came in at $0.02 , while revenue for the quarter reached $568.34M .
Earnings released on 30 Aug 2021
EPS came in at $0.05 , while revenue for the quarter reached $553.66M .
Earnings released on 30 Mar 2021
EPS came in at $0.03 , while revenue for the quarter reached $438.65M .
1302.HK Stock Performance
Access detailed 1302.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.